Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated continued positive reception by the industry and collaborators of its exVive3DTM Human Liver Tissue. The product, which was made widely available in full commercial release on November 18, has been recognized as groundbreaking in the field, resulting in several awards for innovation.
Most recently, on December 4, Organovo's exVive3DTM Human Liver Tissue was selected by a panel of industry judges as a CONNECT 2014 Most Innovative Product. CONNECT is a San Diego innovation organization, with membership from over 120 firms and universities, that catalyzes the creation of innovative technology and life sciences products in San Diego. The exVive3DTM Human Liver was selected as the winner from a highly innovative set of competitive research tools and diagnostic products.
Also this month, the exVive3DTM Human Liver Tissue was selected by a separate panel of judges from industry and academia as one of the Top 10 Innovations of 2014 by The Scientist magazine, a widely read and well respected news outlet for life science researchers.
Earlier this year Organovo's liver tissue was also named a Silver award winner in the life science space at the 2014 Edison Awards and the Company was named a 2015 Technology Pioneer by the World Economic Forum.
"Organovo's first-in-class tissue has been very well received by the scientific community," commented Organovo Chief Executive Officer Keith Murphy. "Our current data provides ample evidence for customers to engage in our commercial research services, and we have been honored by a number of awards acknowledging the innovative nature of our product. We look forward to continuing to expand the impact and uptake of the exVive3DTM Human Liver Tissue, along with extending our offering with other equally innovative tissue types."
